A university spin-out has demonstrated that its technology works. Its next goal is to validate it on a customer’s production line. The prototype secured a research grant, and the team now needs capital for tooling, trials and the people who will run them. A prospective investor will want to see what the trial can prove, what the spin-out has the rights to commercialise and who might buy the product if the trial succeeds.

In an interview with James Coe, Stian Westlake, Executive Chair of the UK’s Economic and Social Research Council, starts from a wider question. Why has productivity stagnated while spending on research and development has risen? He describes three roles for UK Research and Innovation. It funds curiosity-driven research, supports applied R&D that can attract private investment, and helps businesses start and scale in the UK. Westlake sees access to growth capital as one of several conditions that determine whether research translates into economic gains. Research Agenda

The proposed European Innovation Act approaches part of that problem through intellectual property. The Commission proposes a Competence Centre at the EUIPO and a voluntary EU framework for valuing and disclosing IP assets. Our question for this edition is how those measures could help a company demonstrate that the assets created in a research project can support the next commercial step. European Commission proposal

Stian Westlake and the evidence of demand

Westlake cites advance market commitments in quantum computing as an example of how public policy can help create a market. The prospect of a customer buying a technology if it meets agreed conditions gives a developer a clearer target and gives investors something concrete to assess. At company level, a pilot can serve a similar purpose when the customer specifies the conditions under which it would move from a trial to deployment. The IP assessment can then focus on the capability the customer is willing to pay for and the rights the company needs to deliver it. Research Agenda

Anke Nestler and Meloria Meschi on what makes data valuable

At a Licensing Executives Society Germany discussion, Anke Nestler and Meloria Meschi of FTI Consulting examined when data becomes a valuable asset, which rights can be relevant and how its value can be assessed. Consider a spin-out whose product depends on a dataset assembled during a joint research project. To estimate its contribution to future sales, the company first needs to establish which data it can continue using commercially and on what terms. The financial question then becomes more specific. How much would it cost to reproduce that dataset, and what would customers lose if the product had to rely on data that was easier to obtain? LES Germany

Stefan Rüssli and what a buyer can take over

In a post on Swiss SME succession, Stefan Rüssli identifies dependence on the current owner as one obstacle to a sale. The same question can arise in a research spin-out. A company may have a licence to a patent while the university team still holds the practical knowledge needed to reproduce the process. A buyer or licensee considering the technology will need to know which capabilities can be handed over, what documentation and training come with them, and which permissions are needed for a transfer. These facts shape what a prospective buyer can do with the IP and what it might pay. Stefan Rüssli on LinkedIn

Andrea Di Carlo and Nina Dremelj on financing at scale

At the Web Summit in Lisbon on 11 November, EUIPO Deputy Executive Director Andrea Di Carlo and Business Angels Slovenia President Nina Dremelj addressed the barriers to scaling IP-backed finance. The two institutions they represent bring different decisions into view. An equity investor can ask how exclusive access to a technology supports the company’s growth prospects. A lender needs to assess how the company will repay the loan and what could be recovered if the plan falls short. Both may start with the same evidence on ownership, licensing terms and customer demand. They will use that evidence to answer different questions. Web Summit session

That distinction matters for the European proposal. A common framework can help companies present IP evidence in a form that different finance providers can use. Actual transactions will show which information each provider relies on and how much it costs a company to produce it. WIPO’s IP Finance Dialogue on 24 November is due to showcase pilots and examine how IP assessment can enter financing decisions. One question to take into those discussions is which piece of IP evidence made a difference to an actual decision on funding or its terms. WIPO IP Finance Dialogue

Preparing for the next financing decision

A management team preparing to fund the next step can begin with four questions.

  • What will the next investment allow us to prove, and who will make a decision once we have that evidence?
  • Which rights, data and know-how do we need to reach that milestone? Who controls them?
  • Which of those assets could a partner or buyer use, and what would have to be transferred with them?
  • What would give an investor or lender enough confidence to commit, and what happens to the value of the assets if the milestone slips?

For the spin-out preparing its first factory trial, those questions could change what the team does before it raises capital. It might secure continued rights to use the trial data, document the process with the university team and agree with the customer what results would justify a paid deployment. The next funder can then assess a specific commercial opportunity and the IP that makes it possible.

Further reading

Building IP That Survives the Transition from Clean-Tech R&D to Market
Maeve O’Flynn and Jamie Barcombe explain how industrial pilots can create new IP and why partners should agree who can use the results.

Commercial Implications of IP Assignments
How ownership and restrictions on transfer can affect licensing, financing and a later sale.

IP Valuation in the Digital IP Lexicon (dIPlex)
How the purpose of a valuation shapes the choice of method and the evidence it requires.

WIPO IP Finance Dialogue 2025
A look at how lenders assess IP as collateral, from confidence in the valuation to potential recovery in the event of default.